Functional profiling of Covid 19 vaccine candidate by flow virometry.
Covid 19 vaccine
Flow virometry
SARS-CoV-2 spike protein
Vaccine development
Vesicular stomatitis virus
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
02 09 2022
02 09 2022
Historique:
received:
16
11
2021
revised:
20
05
2022
accepted:
03
08
2022
pubmed:
20
8
2022
medline:
9
9
2022
entrez:
19
8
2022
Statut:
ppublish
Résumé
Vaccine development is a complex process, starting with selection of a promising immunogen in the discovery phase, followed by process development in the preclinical phase, and later by clinical trials in tandem with process improvements and scale up. A large suite of analytical techniques is required to gain understanding of the vaccine candidate so that a relevant immunogen is selected and subsequently manufactured consistently throughout the lifespan of the product. For viral vaccines, successful immunogen production is contingent on its maintained antigenicity and/or infectivity, as well as the ability to characterize these qualities within the context of the process, formulation, and clinical performance. In this report we show the utility of flow virometry during preclinical development of a Covid 19 vaccine candidate based on SARS-CoV-2 spike (S) protein expressed on vesicular stomatitis virus (VSV). Using a panel of monoclonal antibodies, we were able to detect the S protein on the surface of the recombinant VSV virus, monitor the expression levels, detect differences in the antigen based on S protein sequence and after virus inactivation, and monitor S protein stability. Collectively, flow virometry provided important data that helped to guide preclinical development of this vaccine candidate.
Identifiants
pubmed: 35985887
pii: S0264-410X(22)00963-X
doi: 10.1016/j.vaccine.2022.08.006
pmc: PMC9359933
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5529-5536Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Josef Vlasak reports financial support was provided by US Department of Health and Human Services.
Références
J Virol. 2002 Oct;76(19):10038-43
pubmed: 12208982
Science. 2010 Feb 5;327(5966):689-93
pubmed: 20133572
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
J Virol. 2020 Jan 6;94(2):
pubmed: 31694951
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
J Pharm Pract. 2022 Dec;35(6):947-951
pubmed: 33840294
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Curr Protoc Cytom. 2015 Jul 01;73:13.14.1-13.14.16
pubmed: 26132176
J Virol. 2018 Jan 17;92(3):
pubmed: 29167334
Sci Rep. 2017 Apr 19;7(1):948
pubmed: 28424455
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Virology. 2016 Jan 15;488:20-7
pubmed: 26590794
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Sci Rep. 2021 Apr 1;11(1):7432
pubmed: 33795759
Vaccine. 2016 Apr 29;34(20):2321-8
pubmed: 27020711
J Virol. 2020 Feb 28;94(6):
pubmed: 31852789
J Virol. 2017 Mar 13;91(7):
pubmed: 28077654
PLoS Pathog. 2021 Jan 25;17(1):e1009246
pubmed: 33493182
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Virol. 2014 Dec;88(24):14197-206
pubmed: 25275126
Viruses. 2021 Mar 26;13(4):
pubmed: 33810401